Financial Report: Merck 1Q

1Q Revenues:$11.4 billion (revenues were $5.4 billion in 1Q09)

1Q Earnings: $330.2 million (-77%)

Comments: Revenuegrowth in the quarteris largely due to the inclusion of legacy Schering-Plough operations. Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%). Nasonex sales were $320 million (+4%). Fosamax sales were $230 million (-12%). Clarinex sales were flat at $174 million. Zetia sales were up 5% to $534 million. Vytorin sales were flat at $477 million. Januvia and Janumet sales were $511 million (+24%) and $201 million (+56%), respectively. Isentress sales were up 57% to $232 million. Cozaar / Hyzaar sales were $782 million (-7%). Varivax sales were $319 million (+27%). Gardasil sales were down 11% to $233 million. R&D expenses were up 66% to $2.0 billion. Results include $2.3 billion of expenses related to the Merck/Schering-Plough merger. Restructuring costs were $287.7 million in the quarter.